We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Mucin Protein Is a New Prognostic Biomarker for Chronic Obstructive Pulmonary Disease

By LabMedica International staff writers
Posted on 15 Jun 2021
The mucin protein MUC5AC has been shown to be a novel biomarker for chronic obstructive pulmonary disease (COPD) prognosis and for testing the efficacy of potential therapeutic agents.

COPD is an inflammatory lung disease that causes obstructed airflow from the lungs and affects about 16 million people in the USA. More...
Symptoms include breathing difficulty, coughing, mucus production, and wheezing. Development of COPD has been linked to long-term exposure to irritants and especially to cigarette smoking.

Investigators at the University of North Carolina (Chapel Hill, USA) previously described the contributions of increased total airway mucin concentrations to the pathogenesis and diagnosis of the chronic bronchitic component of COPD.

In the current study, they investigated the relative contribution of each of the major airway gel-forming mucins, MUC5AC and MUC5B, to the initiation, progression, and early diagnosis of airways disease in COPD. Over the course of the study, they used stable isotope-labelled mass spectrometry to measure levels of MUC5AC and MUC5B in induced sputum samples taken from 331 participants (mean age 63 years) in the multicenter SPIROMICS study, of whom 40 were healthy nonsmokers, 90 were at-risk smokers, and 201 were smokers with COPD. Participants were extensively characterized using results from a variety of questionnaires,

Results revealed that increased MUC5AC concentrations were more reliably associated with manifestations of COPD than were MUC5B concentrations. Increased MUC5AC, but not MUC5B, concentration at baseline was a significant predictor of COPD progression during the three-year follow-up period. Moreover, current smokers in the at-risk group showed raised MUC5AC concentrations at initial visits and decreased lung function over three years. By contrast, former smokers in the at-risk group showed normal MUC5AC concentrations at the initial visit and preserved lung function over three years.

"Currently, we cannot forecast which individuals in the at-risk smokers group will progress to COPD because we do not have an objective biological marker to underpin the disease-causing pathways. Our research shows that MUC5AC could be a predictor of who will develop COPD from the large group of aging "at-risk" smokers," said senior author Dr. Mehmet Kesimer, professor of pathology and laboratory medicine at the University of North Carolina. "We think MUC5AC could be a new biomarker for COPD prognosis and it could be a biomarker for testing the effectiveness of therapeutic strategies. Our data indicate that increased MUC5AC concentrations in the airways may contribute to the initiation of COPD, as well as disease progression, symptom exacerbation, and how the disease progresses over time, in general. We did not observe the same association with MUC5B."

The study was published in the May 28, 2021, online edition of the journal The Lancet Respiratory Medicine.

Related Links:
University of North Carolina


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.